Drug recall · March 1, 2023
TIROSINT - SOL recall
Why: Subpotent Drug
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5
- Lots / codes
Lot #: 220414, Exp. 10/2023; 220852, Exp. 02/2024; 220970, Exp. 03/2024.
- Quantity
- N/A
- Company
- Ibsa Pharma Inc, Parsippany, NJ
- Distribution
- Nationwide in the USA.
- Initiated
- January 30, 2023 · Voluntary: Firm initiated
- Classified
- April 4, 2023
- Reported
- March 1, 2023
- Ended
- October 31, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Levothyroxine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.